Metabolism of nicotinic acid in children with burns and scalds

Barlow, George; Sutton, Judith L.; Wilkinson, A. W.

doi:10.1016/0009-8981(77)90206-6

Cited by 19 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It could be speculated that the adequate urinary MNA in our HIV‐positive children reflected a disease condition rather than a deficiency state (29). Further investigations are needed to confirm this hypothesis.…”

Section: Discussionmentioning

confidence: 99%

Niacin Nutritional Status in HIV Type 1–Positive Children: Preliminary Data

Tremeschin

Cervi²,

Júnior³

et al. 2007

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Niacin Nutritional Status in HIV Type 1–Positive Children: Preliminary Data

Tremeschin

Cervi²,

Júnior³

et al. 2007

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

show abstract

“…Although it has been reported that urinary excretion of Met2PY and other nicotinamide catabolites is significantly enhanced in children with burns and scalds [7] as well as in adult patients with primary affective disorders [8] or liver cirrhosis [9], the urinary excretion of Met2PY in a patient with Parkinson's disease seems to be decreased [10]. These data suggest that the nicotinamide metabolism could be affected in a different way in disease conditions.…”

Section: Introductionmentioning

confidence: 94%

Accumulation of poly(ADP-ribose) polymerase inhibitors in children with chronic renal failure

et al. 2006

View full text Add to dashboard Cite

Nicotinamide, N-methyl-2-pyridone-5-carboxamide (Met2PY) and N-methyl-4-pyridone-3-carboxamide (Met4PY) are biological metabolites of the intracellular coenzyme nicotinamide adenine dinucleotide (NAD) that can potentially inhibit poly(ADP-ribose) polymerase 1 (PARP-1; DNA repair enzyme). Our research was aimed at establishing whether chronic renal failure (CRF) in children leads to the elevation of plasma NAD metabolites sufficient to inhibit PARP-1 activity. Nicotinamide, Met2PY and Met4PY plasma and erythrocyte concentrations were measured in 25 children with CRF and in 19 healthy children. The effect of these NAD metabolites on PARP-1 activity was studied in vitro. We found that plasma concentration of all NAD metabolites (nicotinamide, Met2PY, Met4PY) in children with CRF could reach the concentration of 2, 30 and 10 microM as compared to 0.2, 1 and 0.5 microM, respectively, in healthy children. The concentration of nicotinamide metabolites correlated positively with plasma creatinine concentration and negatively with creatinine clearance in children with CRF. We found that Met2PY, Met4PY and nicotinamide inhibited in vitro PARP-1 activity with IC50 values of 2.1, 0.18 and 0.12 mM, respectively. Our data indicate that NAD metabolites accumulate in plasma of children with CRF and their combined effect could lead to the inhibition of PARP-1 activity. NAD metabolites could be particularly harmful in children due to higher DNA turnover than in adults.

show abstract

“…Changes in the plasma concentration of MNA have been reported in many pathological states, including Parkinson's disease [11], affective disorders [12], burns in children [13], as well as liver cirrhosis [14]. In the light of the vasoprotective activity of MNA, a rise in the plasma MNA concentration [15] may represent an important compensatory mechanism triggered by inflammation or injury.…”

Section: Introductionmentioning

confidence: 99%